¿Qué aporta prosigna en el tratamiento adyuvante de pacientes con cáncer de mama? - page 15

(J Clin Oncol 2016)
HR+/HER-neg and NODE-negative
INDICATION Evidence Quality Recomendation Strenght
PAM 50 ROR YES HIGH STRONG
HR+/HER-neg and NODE-positive
INDICATION Evidence Quality Recomendation Strenght
PAM 50 ROR NO INTERMEDIATE MODERATE
Low risk of late recurrence
INDICATION Evidence Quality Recomendation Strenght
PAM 50 ROR NO INTERMEDIATE MODERATE